← Back to Screener
Adaptive Biotechnologies Corporation Common Stock (ADPT)
Price$14.58
Favorite Metrics
Price vs S&P 500 (26W)-13.36%
Price vs S&P 500 (4W)-2.94%
Market Capitalization$2.23B
All Metrics
Book Value / Share (Quarterly)$1.42
P/TBV (Annual)11.42x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)14.34%
Cash Flow / Share (Quarterly)$-0.32
Price vs S&P 500 (YTD)-15.04%
Gross Margin (TTM)74.24%
Net Profit Margin (TTM)-21.48%
EPS (TTM)$-0.40
10-Day Avg Trading Volume1.84M
EPS Excl Extra (TTM)$-0.40
Revenue Growth (5Y)23.00%
EPS (Annual)$-0.39
ROI (Annual)-17.00%
Gross Margin (Annual)74.24%
Net Profit Margin (5Y Avg)-97.06%
Cash / Share (Quarterly)$1.48
Revenue Growth QoQ (YoY)51.04%
ROA (Last FY)-11.60%
Revenue Growth TTM (YoY)54.77%
EBITD / Share (TTM)$-0.29
ROE (5Y Avg)-51.27%
Operating Margin (TTM)-20.62%
Cash Flow / Share (Annual)$-0.32
P/B Ratio10.18x
P/B Ratio (Quarterly)11.33x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)8.26x
Net Interest Coverage (TTM)-24.47x
ROA (TTM)-11.84%
EPS Incl Extra (Annual)$-0.39
Current Ratio (Annual)3.34x
Quick Ratio (Quarterly)3.10x
3-Month Avg Trading Volume2.11M
52-Week Price Return93.19%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.41
P/S Ratio (Annual)8.04x
Asset Turnover (Annual)0.54x
52-Week High$20.76
Operating Margin (5Y Avg)-97.65%
EPS Excl Extra (Annual)$-0.39
CapEx CAGR (5Y)-30.91%
Tangible BV CAGR (5Y)-21.61%
26-Week Price Return-4.61%
Quick Ratio (Annual)3.10x
13-Week Price Return-19.79%
Total Debt / Equity (Annual)0.60x
Current Ratio (Quarterly)3.34x
Enterprise Value$2,288.826
Revenue / Share Growth (5Y)19.47%
Asset Turnover (TTM)0.55x
Book Value / Share Growth (5Y)-23.42%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)7.82x
Pretax Margin (Annual)-21.47%
Cash / Share (Annual)$1.48
3-Month Return Std Dev66.33%
Gross Margin (5Y Avg)65.28%
Net Income / Employee (TTM)$-0
ROE (Last FY)-27.19%
Net Interest Coverage (Annual)-24.47x
EPS Basic Excl Extra (Annual)$-0.39
Receivables Turnover (TTM)6.01x
Total Debt / Equity (Quarterly)0.60x
EPS Incl Extra (TTM)$-0.40
Receivables Turnover (Annual)6.01x
ROI (TTM)-17.98%
P/S Ratio (TTM)8.04x
Pretax Margin (5Y Avg)-97.09%
Revenue / Share (Annual)$1.83
Tangible BV / Share (Annual)$1.41
Price vs S&P 500 (52W)58.10%
Year-to-Date Return-10.90%
5-Day Price Return2.41%
EPS Normalized (Annual)$-0.39
ROA (5Y Avg)-24.21%
Net Profit Margin (Annual)-21.48%
Month-to-Date Return4.25%
Cash Flow / Share (TTM)$-1.21
EBITD / Share (Annual)$-0.30
Operating Margin (Annual)-20.62%
LT Debt / Equity (Annual)0.58x
ROI (5Y Avg)-38.64%
LT Debt / Equity (Quarterly)0.58x
EPS Basic Excl Extra (TTM)$-0.40
P/TBV (Quarterly)11.42x
P/B Ratio (Annual)11.33x
Inventory Turnover (TTM)7.82x
Pretax Margin (TTM)-21.47%
Book Value / Share (Annual)$1.42
Price vs S&P 500 (13W)-22.65%
Beta2.23x
P/FCF (Annual)11.47x
Revenue / Share (TTM)$1.81
ROE (TTM)-30.00%
52-Week Low$6.77
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.21
4.21
4.21
4.21
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ADPTAdaptive Biotechnologies Corporation Common Stock | 8.04x | 54.77% | 74.24% | — | $14.58 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Adaptive Biotechnologies develops diagnostic tests that leverage the adaptive immune system to detect and monitor cancer. The company's flagship product, clonoSEQ, is FDA-authorized for minimal residual disease monitoring in patients with multiple myeloma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. The test is also available as a CLIA-validated service for other lymphoid malignancies, including diffuse large B-cell lymphoma.